Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EU-RESPONSE

Financiado

Cerrado

European Research and Preparedness Network for Pandemics and Emerging Infectious...

European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases The overall objective of this 5-year project is to build a multinational, adaptive European COVID-19 and emerging infectious diseases trial network, based on existing initiatives, experience and expertise, allowing European expans... ver más

30/06/2025

INSERM

16M€

Presupuesto del proyecto: 16M€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 26 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-09-03 No tenemos la información de la convocatoria

0% 98% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

26 Participantes

INSERM

6.18M€ | Lider

USZ

41.72K€ | Participante

UCC

378.97K€ | Participante

SORBONNE UNIVERSITE

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ISIDORe Integrated Services for Infectious Disease Outbreak Research 21M€ Cerrado

NAVIPP New AntiVirals for Infections with Pandemic Potential 6M€ Cerrado

ISIDORe Integrated Services for Infectious Disease Outbreak Research 21M€ Cerrado

PID2021-127496NB-I00 ANALISIS DE LAS BASES MOLECULARES DE LA INTERACCION SARS-COV... 133K€ Cerrado

PROYECTO DE INVESTIGACIÓN PARA LA EVALUACIÓN... PROYECTO DE INVESTIGACIÓN PARA LA EVALUACIÓN DE LA EFICACIA... 1M€ Cerrado

ECRAID-Base European Clinical Research Alliance on Infectious Diseases 30M€ Cerrado

Duración del proyecto: 57 meses Fecha Inicio: 2020-09-03
Fecha Fin: 2025-06-30

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 16M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The overall objective of this 5-year project is to build a multinational, adaptive European COVID-19 and emerging infectious diseases trial network, based on existing initiatives, experience and expertise, allowing European expansion of DisCoVeRy (WP1) and the establishment of a COVID19 adaptive platform trial (WP2). The DisCoVeRy trial, designed as a multi-arm adaptive repurposing trial, initiated in France, has the potential to expand to many other European countries with appropriate support in terms of multinational funding and trial management capacity. This will complete the evaluation of repurposed drugs, while building a European clinical trial network which, together with other European networks such as the Solidarity trial, will design and run a new European platform trial. EU-RESPONSE will swiftly generate robust evidence for drug repurposing or registration, through a modular trial framework allowing most European hospitals to participate at their preferred level of commitment, thus building a network of investigation sites within European and associated countries. Cooperation with other European platforms, in particular the RECOVER consortium platform will be achieved through a joint coordination mechanism aligned with European and national policies (WP3), ensuring a coordinated strategy for the European COVID-19 Adaptive Platform Trials, their complementarity in providing access for requests for a new domain or arm, their synergy and cross-fertilization through the development of a common toolbox for the development and the management of Adaptive Platform Trials. Joining forces in Europe and with international partners, it will contribute to the global clinical trial capacity for urgently meeting the expectations of society and developers. It will also boost multinational cooperation in Europe and promote the establishment of adaptive platform trials in other diseases, and will have a major impact on epidemic control.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores